Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> MutationFrank J. Accurso, Bonnie W. Ramsey, Michael W. Konstan et al.|New England Journal of Medicine|2010Cited by 802
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Jessica Carey, Félix Ratjen et al.|The Lancet Respiratory Medicine|2022Cited by 128
Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftorDon B. Sanders, Elizabeth A. Cromwell, Nicole Mayer-Hamblett et al.|Journal of Cystic Fibrosis|2024Cited by 11
Rapid lung function decline in adults with early-stage cystic fibrosis lung diseaseElliott C. Dasenbrook, Nicole Mayer-Hamblett, Aliza K. Fink et al.|Journal of Cystic Fibrosis|2019Cited by 3